UBS Group AG Decreases Stake in GH Research PLC $GHRS

UBS Group AG lowered its stake in GH Research PLC (NASDAQ:GHRS) by 29.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 363,381 shares of the company’s stock after selling 148,083 shares during the period. UBS Group AG owned 0.70% of GH Research worth $4,615,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in GHRS. JPMorgan Chase & Co. purchased a new position in shares of GH Research in the second quarter worth $79,000. BNP Paribas Financial Markets raised its holdings in shares of GH Research by 165.4% in the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after buying an additional 10,600 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after buying an additional 2,400 shares during the last quarter. AdvisorShares Investments LLC raised its holdings in shares of GH Research by 41.1% in the third quarter. AdvisorShares Investments LLC now owns 53,991 shares of the company’s stock worth $772,000 after buying an additional 15,735 shares during the last quarter. Finally, CenterBook Partners LP purchased a new position in shares of GH Research during the third quarter worth $2,376,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Stock Up 1.6%

Shares of GHRS stock opened at $22.12 on Friday. The stock has a market cap of $1.52 billion, a PE ratio of -24.04 and a beta of 1.27. The business has a 50-day simple moving average of $17.78 and a 200-day simple moving average of $15.82. GH Research PLC has a 52-week low of $10.66 and a 52-week high of $24.66.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Sell-side analysts anticipate that GH Research PLC will post -1.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

GHRS has been the subject of several recent research reports. Royal Bank Of Canada raised their target price on shares of GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Cantor Fitzgerald lifted their price objective on GH Research from $25.00 to $35.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. HC Wainwright decreased their price objective on GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday. Citigroup reissued an “outperform” rating on shares of GH Research in a report on Friday, May 15th. Finally, Guggenheim set a $34.00 price objective on GH Research and gave the company a “buy” rating in a report on Tuesday, March 10th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $40.38.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.